

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation of offer to acquire, purchase or subscribe for securities.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code on GEM: 8199)

(Stock Code on Main Board: 1066)

**TRANSFER OF LISTING FROM THE GROWTH ENTERPRISE MARKET TO
THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

On 9 June 2010, an application was made by Shandong Weigao Group Medical Polymer Company Limited (the "Company") to the Stock Exchange for the listing of, and permission to deal in, the 428,121,081 H Shares in issue by way of transfer of the listing from GEM to the Main Board. The Board is pleased to announce that the approval for the Transfer of Listing has been granted by the CSRC on 20 April 2010, and the approval-in-principle for the Transfer was granted by the Stock Exchange on 19 July 2010 for the H Shares to be listed on the Main Board and de-listed from GEM Board according to Main Board Listing Rule 9A.09(6). All pre-conditions for the Transfer as set out in Rule 9A.02 of the Main Board Listing Rules have been fulfilled in relation to the Company and its H Shares. Immediately prior to the listing of the H Shares on the Main Board, the listing of the existing H Shares on GEM will be withdrawn. The last day of dealings in the Shares on GEM is 28 July 2010. Dealings in the H Shares on the Main Board (Stock code: 1066) will commence at 9:30 a.m. on 29 July 2010.

* For identification purpose only

FREE EXCHANGE OF SHARE CERTIFICATE

Subject to the listing of the H Shares on the Main Board becoming effective, H Shareholders may submit existing certificates for the H Shares listed on GEM Board in board lot of 4,000 H Shares to Hong Kong H Shares registrar of the Company, Tricor Standard Limited, at 26th Floor, Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong for exchange from Thursday, 29 July 2010 to Friday, 27 August 2010 (both dates inclusive), at the expense of the Company for certificates for the H Shares listed on the Main Board remains in board lot of 4,000 H Shares. Thereafter, certificates for the H Shares listed on Main Board will be accepted for exchange only on payment of a fee of HK\$2.5 (or such higher amount as may from time to time be allowed by the Stock Exchange) for each new share certificate issued for the H Shares listed on the Main Board. Nevertheless, the existing certificates for the H Shares listed on GEM Board will continue to be good evidence of legal title and will be valid for dealings, trading and settlement purpose after the transfer of listing of H Shares from GEM to the Main Board has become effective and may be exchanged for certificates for the H Shares listed on the Main Board at any time in accordance with the foregoing.

For ease of reference, the H Shares will continue to be traded in board lots of 4,000 H Shares each and the trading currency will continue to be Hong Kong dollars.

TRANSFER OF LISTING FROM GEM TO MAIN BOARD

On 9 June 2010, an application was made by the Company to the Stock Exchange for the listing of, and permission to deal in, the 428,121,081 H Shares in issue by way of transfer of the listing from GEM to the Main Board. The Board is pleased to announce that the approval for the Transfer of Listing has been granted by the CSRC on 20 April 2010, and the approval-in-principle for the Transfer was granted by the Stock Exchange on 19 July 2010 for the H Shares to be listed on the Main Board and de-listed from GEM Board according to Main Board Listing Rule 9A.09(6). Immediately prior to the listing of the H Shares on the Main Board, the listing of the existing H Shares on GEM will be withdrawn. The last day of dealings in the Shares on GEM is 28 July 2010. Dealings in the H Shares on the Main Board (Stock code: 1066) will commence at 9:30 a.m. on 29 July 2010.

FREE EXCHANGE OF SHARE CERTIFICATE

Subject to the listing of the H Shares on the Main Board becoming effective, H Shareholders may submit existing certificates for the H Shares listed on GEM Board in board lot of 4,000 H Shares to Hong Kong H Shares registrar of the Company, Tricor Standard Limited, at 26th Floor, Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong for exchange from Thursday, 29 July 2010 to Friday, 27 August 2010 (both dates inclusive), at the expense of the Company for certificates for the H Shares listed on the Main Board remains in board lot of 4,000 H Shares. Thereafter, certificates for the H Shares listed on Main Board will be accepted for exchange only on payment of a fee of HK\$2.5 (or such higher amount as may from time to time be allowed by the Stock Exchange) for each new share certificate issued for the H Shares listed on the Main Board. Nevertheless, the existing certificates for the H Shares listed on GEM Board will continue to be good evidence of legal title and will be valid for dealings, trading and settlement purpose after the transfer of listing of H Shares from GEM to the Main Board has become effective and may be exchanged for certificates for the H Shares listed on the Main Board at any time in accordance with the foregoing.

For ease of reference, the H Shares will continue to be traded in board lots of 4,000 H Shares each and the trading currency will continue to be Hong Kong dollars.

The H Shares have been accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from 27 February 2004, the date on which the H Shares were first listed on GEM. Subject to the continual compliance with the stock admission requirements of HKSCC, the H Shares will continue to be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS once dealings in the H Shares on the Main Board commence. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

All pre-conditions for the Transfer as set out in Rule 9A.02 of the Main Board Listing Rules have been fulfilled in relation to the Company and its H Shares. Immediately prior to the listing of the H Shares on the Main Board, the listing of the existing H Shares on GEM will be withdrawn. The last day of dealings in the Shares on GEM is 28 July 2010. Dealings in the H Shares on the Main Board (Stock code: 1066) will commence at 9:30 a.m. on 29 July 2010.

REASONS FOR THE TRANSFER

The Company has been listed on GEM since 27 February 2004. In the past few years, the Group has experienced fast expansion. The Board believes that the listing of the H Shares on the Main Board may enhance the profile of the Group and increase the trading liquidity of the H Shares. The Directors consider that the listing of the H Shares on the Main Board will be beneficial to the future growth, financial flexibility and business development of the Group. No material change in the business of the Group is currently being contemplated by the Directors following the Transfer. The Transfer will not involve issue of any new H Shares by the Company.

GENERAL MANDATES TO ISSUE SHARES

The general mandates granted to the Board to allot and issue new H Shares by the Shareholders on 10 May 2010 has no specific references to the GEM Listing Rules and will remain valid and with effect when the listing of the H Shares is transferred to the Main Board until the earliest of:-

- (a) the conclusion of the next annual general meeting of the Company;
- (b) the expiration of the period within which the next annual general meeting of the Company is required by its articles of association or any applicable laws of the People's Republic of China to be held; or
- (c) the revocation or variation of such authority by an ordinary resolution of H Shareholders in general meeting.

COMPETING INTERESTS

As at the date of this announcement, none of the Directors, management shareholders and controlling shareholders of the Company and their respective associates has an interest in a business which competes or may compete, either directly or indirectly, with the business of the Group pursuant to Main Board Listing Rule 9A.09(10) of the Main Board Listing Rules.

BIOGRAPHICAL INFORMATION OF DIRECTORS

The Company discloses the biographical information of each Director as follows:

Executive Directors

Mr. Zhang Hua Wei, age 47, is the vice chairman and general manager of the Company and vice chairman of Weigao Holding Company Limited (“Weigao Holding”). Mr. Zhang studied politics and economics at the Weihai Campus of Shandong University from 1996 to 1998. Mr. Zhang was the deputy factory director of Weigao Holding from 1988 to 1998, and has been the general manager of Weigao Holding since 1998. Mr. Zhang joined the Company in December 2000. Save as disclosed above, Mr. Zhang did not hold any other directorship in any listed companies during the last 3 years. Mr. Zhang is entitled to an annual remuneration with a maximum of RMB800,000. There is no agreement in respect of the director’s remuneration of Mr. Zhang and his director’s remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders’ approval at the AGM. There is a service contract entered into between the Company and Mr. Zhang for a term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Zhang holds 29,280,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Mr. Zhang holds 8,100,000 non-listed shares in the Company and together with Weigao Holding, 5 directors, Mr. Chen Lin and a senior management of the Company, in aggregate, hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company. Save as disclosed above, Mr. Zhang does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Zhang does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, the Board is not aware of any information that ought to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Mr. Wang Yi, age 51, is an executive Director and deputy general manager of general affairs of the Company. Mr. Wang studied Business Administration at the Shandong Cadres Distance Learning University from 1994 to 1997. He joined Weigao Holding in 1988 and was production director from 1988 to 1989, head of the No. 2 branch of Weigao Holding from 1989 to 1992 and manager of the No. 3 branch of Weigao Holding from 1992 to 2004. Mr. Wang joined the Company in December 2000. Save as disclosed above, Mr. Wang did not hold any other directorship in any listed companies during the last 3 years. Mr. Wang is entitled to an annual remuneration with a maximum of RMB600,000. There is no agreement in respect of the director's remuneration of Mr. Wang and his director's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. There is a service contract entered into between the Company and Mr. Wang for a term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Wang holds 7,320,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Mr. Wang, holds 5,850,000 non-listed shares in the Company and together with Weigao Holding, 5 directors, Mr. Chen Lin and a senior management of the Company, in aggregate, hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company. Save as disclosed above, Mr. Wang does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Wang does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Wang has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Mr. Miao Yan Guo, age 47, is an executive Director and deputy general manager of research and development of the Company. Mr. Miao studied Business Administration at the Weihai Campus of Shandong University from 1999 to 2001. Mr. Miao joined Weigao Holding in 1988 and was sales director from 1988 to 1991, operating manager from 1991 to 1993 and head of the No. 1 branch of Weigao Holding from 1993 to 1998. He was a deputy general manager of Weigao Holding from 1998 to 2000. Mr. Miao joined the Company in December 2000. Save as disclosed above, Mr. Miao did not hold any other directorship in any listed companies during the last 3 years. Mr. Miao is entitled to an annual remuneration with a maximum of RMB300,000. There is no agreement in respect of the director's remuneration of Mr. Wang and his director's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. There is a

service contract entered into between the Company and Mr. Miao for a term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Miao holds 7,320,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Mr. Miao also holds 5,850,000 non-listed shares in the Company and together with, Weigao Holding, 5 directors, Mr. Chen Lin and a senior management of the Company, in aggregate hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company. Save as disclosed above, Mr. Miao does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Miao does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Miao has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Mr. Wang Zhi Fan, age 54, is an executive Director and deputy general manager of sales of the Company. He joined Weigao Holding in 1988 and was the production head and the manager of foreign trade of Weigao Holding. Mr. Wang joined the Group in December 2000. Save as disclosed above, Mr. Wang did not hold any other directorship in any listed companies during the last 3 years. Mr. Wang is entitled to an annual remuneration with a maximum of RMB400,000. There is no agreement in respect of the director's remuneration of Mr. Wang and his director's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. There is a service contract entered into between the Company and Mr. Wang for a term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Wang holds 2,610,800 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Mr. Wang also holds 2,025,000 non-listed shares in the Company and together with Weigao Holding, 5 directors, Mr. Chen Lin and a senior management of the Company, in aggregate, hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company. Save as disclosed above, Mr. Wang does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Wang does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Wang has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Mr. Wu Chuan Ming, age 52, is an executive Director and deputy general manager of production of the Company. Mr. Wu joined Weigao Holding in 1988. He has been the manager of the blood transfusion branch from 1996 to 2004. He joined the Group in December 2000. Save as disclosed above, Mr. Wu did not hold any other directorship in any listed companies during the last 3 years. Mr. Wu is entitled to an annual remuneration with a maximum of RMB300,000. There is no agreement in respect of the director's remuneration of Mr. Wu and his director's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. There is a service contract entered into between the Company and Mr. Wu for a term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Wu holds 2,257,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Mr. Wu also holds 1,800,000 non-listed shares in the Company and together with Weigao Holding, 5 directors, Mr. Chen Lin and a senior management of the Company, in aggregate, hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company.

Save as disclosed above, Mr. Wu does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Wu does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance. Save as disclosed above, Mr. Wu has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Non-executive Directors

Mr. Chen Xue Li, age 59, is the Chairman of both the Company and Weigao Holding. Mr. Chen founded Weigao Holding in 1988, and was the head of Weigao Holding from 1988 to 1998, Mr. Chen has been elected as the chairman of the Company since December 2000. He received the award of Entrepreneur of Weihai Economy Development in June 2003. Save as disclosed above, Mr. Chen did not hold any other directorship in any listed companies during the last 3 years. Mr. Chen does not entitle to an annual remuneration. There is a service contract entered into between the Company and Mr. Chen for a term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Chen holds 36,600,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Weigao Holding, 6 directors, Mr. Chen Lin, a son of Mr. Chen Xue Li and a senior management of the Company, in aggregate hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company. Save as disclosed above, Mr. Chen does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Chen does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Chen has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Mrs. Zhou Shu Hua, age 53, is a non-executive Director of the Company and financial deputy general manager of Weigao Holding. Mrs. Zhou is also a member of the audit committee of the Company. Mrs. Zhou studied Business Administration at the Weihai Campus of Shandong University from 1999 to 2001. Mrs. Zhou joined Weigao Holding in 1989 and held a number of positions such as head of the finance division in the finance department, manager of the finance department and deputy general manager of Weigao Holding. Save as disclosed above, Mrs. Zhou did not hold any other directorship in any listed companies during the last 3 years. Mrs. Zhou does not entitle to an annual remuneration. There is a service contract entered into between the Company and Mrs. Zhou for a term of three years except that she is subject to retirement by rotation and re-election provisions in the Articles of Association. Mrs. Zhou holds 14,579,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Mrs. Zhou holds 3,825,000 non-listed share in the Company and together with Weigao Holding, 5 directors, Mr. Chen Lin

and a senior management of the Company, in aggregate hold a total of 567,438,919 non-listed shares, which represent approximately 52.7% of the existing shares of the Company. Save as disclosed above, Mrs. Zhou does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mrs. Zhou does not hold any H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mrs. Zhou has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with her appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules, nor is there any other matter that ought to be brought to the attention of the Shareholders.

Mr. Li Bing Yung, age 60, is and has been the President of Medtronic's operations in the Greater China region since February 2007. Prior to his current position, Mr. Li served as vice president of the commercial operations section of Medtronic's operations in the greater China region. Mr. Li has extensive experience in management in the Asia Pacific region. From 1996 to 2005, Mr. Li was with Johnson & Johnson Medical (China) Co. Ltd. where he held a number of executive positions and he was subsequently promoted to International Vice President in North Asia. Mr. Li graduated with a bachelor degree in Social Sciences from the University of Hong Kong in 1976 and obtained a master degree in Business Administration from Henley Management School of the United Kingdom in 1989. Mr. Li was appointed as a non-executive Director of the Company on 15 December 2008. Save as disclosed above, Mr. Li did not hold any other directorship in any listed companies during the last 3 years. Mr. Li does not entitle any remuneration. The appointment of Mr. Li is subject to retirement by rotation and re-election provisions in the Articles of Association. Save as disclosed above, Mr. Li does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Li does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Li has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Mr. Jean-Luc Butel, age 53, is executive vice president of Medtronic, Inc. (“Medtronic”) and the President of Medtronic International Limited. Mr. Butel is responsible for all of Medtronic’s operations outside of the United States. Prior to holding his current position, Mr. Butel served as President of Medtronic in Asia Pacific region and he was responsible for managing and driving all business activities for Medtronic in the Asia Pacific region. Prior to joining Medtronic, he was the president of Independence Technology, a Johnson & Johnson company, where he focused on providing mobility systems for the movement impaired. From 1991 till 1999, he worked for Becton Dickinson, initially as the general manager of its microbiology business in Japan and then as President of Nippon Becton Dickinson. From 1985 to 1991, Mr. Butel was with Johnson & Johnson and served multiple roles including general manager of Fiji, China project manager and marketing director of Johnson & Johnson’s ophthalmic business in Southeast Asia. Mr. Butel has a bachelor degree in International Affairs from George Washington University and a master degree in Business and Administration from American Graduate School of International Management (Thunderbird). Mr. Butel was appointed as a non-executive Director of the Company on 15 December 2008. Save as disclosed above, Mr. Butel did not hold any other directorship in any listed companies during the last 3 years. Mr. Butel does not entitle any remuneration. The appointment of Mr. Butel is subject to retirement by rotation and re-election provisions in the Articles of Association. Save as disclosed above, Mr. Butel does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Li does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Butel has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Independent Non- executive Directors

Mr. Shi Huan, age 73, is an independent non-executive Director and is also a member of the audit committee of the Company. Mr. Shi is the president of China Pharmaceutical Association of Plant Engineering, a senior engineer and a former deputy head of State Pharmaceutical Administrative Bureau. He was appointed as an independent non-executive Director in September 2002. Save as disclosed above, Mr. Shi did not hold any other directorship in any listed companies during the last 3 years. Mr. Shi is entitled to an annual remuneration of RMB72,000. There is a service contract entered into between the Company and Mr. Shi in respect of the director’s remuneration and the service term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles

of Association. Mr. Shi's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Save as disclosed above, Mr. Shi does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Shi does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Shi has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Mr. Luan Jian Ping, age 56, is an independent non-executive Director and is also a member of the audit committee of the Company. Mr. Luan studied philosophy and logic at the People's University of China from 1979 to 1986. He also studied Business Administration at the Aston University in the United Kingdom from 1992 to 1994. He obtained a PRC Lawyer's License issued by the Ministry of Justice of the PRC in October 1996 and is currently a partner of Beijing De Run Law Firm. He was appointed as an independent non-executive Director of the Company in September 2002. Save as disclosed above, Mr. Luan did not hold any other directorship in any listed companies during the last 3 years. Mr. Luan is entitled to an annual remuneration of RMB72,000. There is a service contract entered into between the Company and Mr. Luan in respect of the director's remuneration and the service term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Luan's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Save as disclosed above, Mr. Luan does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Luan does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Luan has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rule.

Mr. Li Jia Miao, age 70, is an independent non-executive Director and is also a member of the audit committee of the Company. Mr. Li is a senior economist and obtained a degree in economics and management in Hohai University in 1998. Mr. Li has over 30 years of pharmaceutical related management experiences and has been an assistant general manager and a general manager in Nanjing Pharmaceutical Company since he joined NPC in 1965. Prior to the retirement of Mr. Li in 2005, he was the chairman of Nanjing Pharmaceutical Company Limited since 2000. He was appointed as an independent non-executive director of the Company on 28 February 2007. Save as disclosed above, Mr. Li did not hold any other directorship in any listed companies during the last 3 years. Mr. Li is entitled to an annual remuneration of RMB72,000. There is a service contract entered into between the Company and Mr. Li in respect of the director's remuneration and the service term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Li's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Save as disclosed above, Mr. Li does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Li does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Li has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Mr. Lo Wai Hung, age 50, obtained a bachelor degree in Commerce from James Cook University of North Queensland, Australia. Mr. Lo is an associate member of Institute of Chartered Accountants in Australia and a fellow member of Hong Kong Institute of Certified Public Accountants. Mr. Lo was appointed as an independent non-executive director, chairman of audit committee and a member of remuneration committee of the Company on 10 August 2009. Save as disclosed above, Mr. Lo did not hold any other directorship in any listed companies during the last 3 years. Mr. Lo is entitled to an annual remuneration of HK\$120,000. There is a service contract entered into between the Company and Mr. Lo in respect of the director's remuneration and the service term of three years except that he is subject to retirement by rotation and re-election provisions in the Articles of Association. Mr. Lo's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Save as disclosed above, Mr. Lo does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Lo does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Lo has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Supervisors

Ms. Bi Dong Mei, age 46, is a supervisor of the Company and the director of the purchase department. Ms. Bi graduated from the Economic Management Department of Shandong Cadres Distance Learning University in 1997. She joined Weigao Holding in December 1988 and has been the head of the finance division and the deputy manager of the infusion sets branch from 2001 to 2004. She joined the Company in December 2000. Save as disclosed above, Ms. Bi did not hold any other directorship in any listed companies during the last 3 years. Ms. Bi is entitled to an annual remuneration with a maximum of RMB400,000. There is a service contract entered into between the Company and Ms. Bi in respect of the supervisor's remuneration and the service term of three years except that she is subject to retirement by rotation and re-election provisions in the Articles of Association. Ms. Bi's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Ms. Bi holds 2,440,000 shares in Weigao Holding, a controlling shareholder holds 49.5% of the issue share capital of the Company. Save as disclosed above, Ms. Bi does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Ms. Bi does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Ms. Bi has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with her appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Mr. Miao Hai Sheng, age 37, is a supervisor of the Company and the project manager of auxiliary pre-filled syringe branch. Mr. Miao graduated from the Weihai Campus of Shandong University in 1997, majoring in operation management. He joined Weigao Holding in 1991 and has been the accountant, finance director, the labour and management officer of Weigao Holding. He joined the Company in December 2000. Save as disclosed above, Mr. Miao did not hold any other directorship in any listed companies during the last 3 years. Mr. Miao is entitled to an annual remuneration with a maximum of RMB240,000. There is a service contract entered into between the Company and Mr. Miao in respect of the director's remuneration and the service term of three years except that he is subject to retirement by

rotation and re-election provisions in the Articles of Association. Mr. Miao's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Save as disclosed above, Mr. Miao does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Mr. Miao does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Miao has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with his appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

Ms. Chen Xiao Yun, age 36, is a supervisor of the Company and the manager of marketing and finance department. Ms. Chen studied financial accounting at the Shandong Broadcast and Television University from 1994 to 1998. She joined Weigao Holding in July 1991 and was the head of the finance division in finance department and the assistant to the manager of infusion sets branch. She joined the Company in December 2000.

Save as disclosed above, Ms. Chen did not hold any other directorship in any listed companies during the last 3 years. Ms. Chen is entitled to an annual remuneration with a maximum of RMB150,000. There is a service contract entered into between the Company and Ms. Chen in respect of the supervisor's remuneration and the service term of three years except that she is subject to retirement by rotation and re-election provisions in the Articles of Association. Ms. Chen's remuneration will be determined by the Board by reference to the market conditions and subject to the shareholders' approval at the AGM. Save as disclosed above, Ms. Chen does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company and Ms. Chen does not hold any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Ms. Chen has confirmed that there are no other matters that need to be brought to the attention of the shareholders in connection with her appointment and no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Main Board Listing Rules.

DOCUMENTS AVAILABLE FOR VIEWING

- (a) The following documents are available for viewing on the website of the Stock Exchange at <http://www.hkexnews.hk> and on the website of the Company at <http://www.weigaogroup.com>:—
- (a) the Directors' report and annual report of the Company for the financial year ended 31 December 2009;
 - (b) the quarterly reports and the interim reports of the Company for the three years ended 31 December 2009 and the first quarterly report for the three months ended 31 March 2010;
 - (c) the memorandum and articles of association of the Company;
 - (d) announcements published by the Company before the date of this announcement as required under the GEM Listing Rules and Main Board Listing Rules.

GENERAL

As at the date of this announcement, none of the controlling shareholders of the Company, the Directors nor their respective associates has any interest in a business that competes or is likely to compete, either directly or indirectly, with the business of the Group. The announcement includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors collectively and individually accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement herein misleading.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms have the meanings set opposite to them below:

“AGM”	the annual general meeting of the Company
“associate”	has the meaning ascribed to it in the Listing Rules;
“Board” or “Directors”	the board of directors of the Company;
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC;
“Company”	Shandong Weigao Group Medical Polymer Company Limited, a joint stock company incorporated in the People’s Republic of China with limited liability and the shares of which are listed on GEM (stock code: 8199);
“controlling shareholder”	has the meaning ascribed to it in the Listing Rules;
“CSRC”	China Securities Regulatory Commission;
“GEM”	the Growth Enterprise Market of the Stock Exchange;
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM;
“Group”	the Company and its subsidiaries;
“HKSCC”	Hong Kong Securities Clearing Company Limited;
“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange;

“Main Board”	the securities market operated by the Stock Exchange prior to the establishment of GEM (excluding the options market) which continues to be operated by the Stock Exchange parallel with GEM. For the avoidance of doubt, the Main Board excludes GEM;
“H Share(s)”	overseas listed foreign invested shares in the ordinary share capital of the Company, with a nominal value of RMB0.10 each, which are to be traded in Hong Kong dollars;
“H Shareholders”	the H shareholders of the Company;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited; and
“Transfer”	the proposed transfer of the listing of the Shares from GEM to Main Board.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Chen Xue Li
Chairman

20 July 2010
Shandong, the PRC

As at the date of the announcement the Board comprises of:–

Executive Director

Mr. Zhang Hua Wei

Mr. Miao Yan Guo

Mr. Wang Yi

Mr. Wang Zhi Fan

Mr. Wu Chuan Ming

Non-executive Director

Mr. Chen Xue Li

Mrs. Zhou Shu Hua

Mr. Li Bing Yung

Mr. Jean-Luc Butel

Independent Non-executive Director

Mr. Shi Huan

Mr. Luan Jian Ping

Mr Li Jia Miao

Mr. Lo Wai Hung

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading; there are no other matters the omission of which would make any statement in this announcement misleading; and all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcement” page for at least seven days from the date of its posting, on the “Listed Company Information” page of the Stock Exchange website at www.hkexnews.hk and on the Company’s website at www.weigaogroup.com.